Innovative mouse model pumps new blood into study of pediatric heart disease

Severe childhood restrictive cardiomyopathy is a condition that causes the muscles in the walls of the heart to become stiff, so that the heart is unable to fill properly with blood. A mutation in a protein called BAG3 is known to result in restrictive cardiomyopathy, muscle weakness, difficulty taking in enough oxygen, and damage to multiple peripheral nerves, often shortening the patient’s lifespan significantly. Until now there has been no successful model for the disease, making it extremely difficult to study.
However, researchers in Japan and Germany have now created a mouse model that mimics the human pathology, allowing the disease to be studied more easily. The team’s data suggest that the restrictive cardiomyopathy caused by BAG3 mutation changes the process by which damaged proteins are broken down and removed. This causes proteins to build up in the cells, disrupting the cardiac muscle.
The team was able to express a human version of the mutant BAG3 protein in mouse cardiomyocytes, the cells that make up the heart muscle. “Our mouse model successfully mimicked the human disease,” says lead author Assistant Professor Kenichi Kimura. “The mice had increasingly severe symptoms of heart failure and growth retardation starting shortly after birth, and only survived for around five weeks.”
The team studied the heart tissue of the mice expressing the mutant human BAG3 protein, and uncovered changes to the protein quality control system, which ensures proteins are correctly folded, alongside increased levels of autophagy, a process by which damaged cells are removed and recycled. BAG3 is involved in the breakdown of proteins that have become damaged due to mechanical stress. The mutation that causes restrictive cardiomyopathy involves the alteration of just a single base in the DNA, leading to a leucine amino acid in the mutant BAG3 protein where there should be a proline.
The team showed that this leads to the mutant protein having reduced solubility and mobility, causing it to build up in the muscle cells. This causes fibrosis, or scarring, and results in the heart muscle stiffening and losing the ability to fully relax, meaning that the heart is unable to properly fill with blood. Moreover, in preliminary investigations using a technique to knockdown and reduce the mutant protein expression, the researchers were able to mitigate the disease symptoms in the mouse model.
Childhood restrictive cardiomyopathy is a rare but very serious disease. Hopefully, the knowledge provided in this study, and the establishment of a mouse model of the disease to support further research, will bring about the development of better treatments for children with this condition.
Story Source:
Materials provided by University of Tsukuba. Note: Content may be edited for style and length.

Read more →

Numerical study reveals origin of 'motion of the ocean' in the straits of Florida

Ocean currents sometimes pinch off sections that create circular currents of water called “eddies.” This “whirlpool” motion moves nutrients to the water’s surface, playing a significant role in the health of the Florida Keys coral reef ecosystem.
Using a numerical model that simulates ocean currents, researchers from Florida Atlantic University’s Harbor Branch Oceanographic Institute and collaborators from the Alfred-Wegener-Institute in Germany and the Institut Universitaire Europeen De La Mer/Laboratoire d’Océonographie Physique et Spatiale in France are shedding light on this important “motion of the ocean.” They have conducted a first-of-its-kind study identifying the mechanisms behind the formation of sub-mesoscale eddies in the Straits of Florida, which have important environmental implications.
Despite the swift flow of the Florida Current, which flows in the Straits of Florida and connects the Loop Current in the Gulf of Mexico to the Gulf Stream in the Western Atlantic Ocean, eddies provide a mechanism for the retention of marine organisms such as fish and coral larvae. Since they trap the nutrient rich West Florida Shelf waters, they provide habitat to many reef and pelagic species within the region of the Florida Keys Reef Track, which sustains the very high productivity of this region.
Moreover, despite the tendency of the West Florida Shelf to overflow into the Straits of Florida, the formation of eddies provides a mechanism that limits the cross shelf transport of nutrient-laden waters. As a result, the formation of eddies stops the export of the West Florida Shelf waters across the Straits of Florida, preventing events such as red tides from crossing over to Cuba or the Bahamas. Conversely, toxic red tide waters emanating from the shelf remain longer in the vicinity of the Florida Keys Reef Tract coral reef ecosystem, adversely affecting the ecosystem’s health.
These small-scale frontal eddies are frequently observed and present a wide variety of numbers, shapes, and sizes, which suggest different origins and formation mechanisms. Their journey through the Straits of Florida is at time characterized by the formation and presence of mesoscale, but mostly sub-mesoscale frontal eddies on the cyclonic side of the current.
The study, published in the Journal of Physical Oceanography, provides a comprehensive overview and understanding of the Straits of Florida shelf slope dynamics based on a realistic two-way nested high-resolution Regional Oceanic Modeling System (ROMS) simulation of the South Florida oceanic region. The full two-way nesting allowed the interaction of multiscale dynamics across the nest boundaries.
Results showed that the formation of the sub-mesoscale frontal eddies in the Straits of Florida are associated with the sloshing of the Florida Current, which consists of the oscillation of the distance of the current core from the shelf. When the Florida Current core is pushed up against the shelf, the shear on the shelf increases and sub-mesoscale frontal eddies can be formed by barotropic instability. When this position is relaxed, baroclinic instability instead is likely to form sub-mesoscale eddies. Unlike barotropic instability, which is shear driven, baroclinic instability is driven by changes in density anomalies.
“In the Straits of Florida, eddies smaller than their open ocean relative are formed. Those eddies, called sub-mesoscale eddies, are common and can be easily observed in ocean color imagery,” said Laurent Chérubin, Ph.D., senior author and an associate research professor, FAU Harbor Branch. “Unlike the larger open ocean mesoscale eddies, they are not in geostrophic balance, meaning that their circulation is not sustained by the balance between the pressure gradient and the Coriolis forces. Instead, some of the frontal eddies in the Straits of Florida are in gradient wind balance, which indicates that a third force, the centrifugal force, is large enough to modify the geostrophic balance.”
The Florida Current is part of the western branch of the wind driven north Atlantic anti-cyclonic gyre, which is intensified on the western side of the North Atlantic basin in comparison to its eastern side. Similar types of currents also are found on the western side of ocean basins such as the Agulhas current in the southern Indian Ocean or the Kuroshio in the northern Pacific Ocean. They are called boundary currents because they impinge on the continental shelf and as such, they undergo a significant amount of friction on the ocean floor. This friction, which acts vertically and horizontally on the boundary current, contributes to the formation of a sheared boundary layer.
“Our study shows that this shear layer can become unstable and form eddies. This process is in fact a pathway for the dissipation of wind energy injected in the ocean. Therefore, in the Straits of Florida, eddies smaller than their open ocean relative are formed,” said Chérubin.
In addition to sub-mesoscale eddies formed locally in the Straits of Florida, there are incoming mesoscale eddies that transit in the Straits of Florida, such as the Tortugas Gyre.
“Findings from our research also show that mesoscale eddies can be squeezed on the shelf and transformed into sub-mesoscale eddies when the Florida Current is in its protracted position or remains relatively unaffected if the Florida Current is retracted from the shelf,” said Chérubin.

Read more →

Meet an Inspiring Researcher Who Helped Create COVID-19 mRNA Vaccines

More than 170 million Americans already have received COVID-19 vaccines. As this number continues to grow and expand to younger age groups, I’m filled with overwhelming gratitude for all of the researchers who worked so diligently, over the course of decades, to build the scientific foundation for these life-saving vaccines. One of them is Dr. Kizzmekia Corbett, who played a central role in the fact that, in the span of less than a year, we were able to develop safe and effective mRNA-based vaccines to protect against this devastating infectious disease.

As leader of the immunopathogenesis team at NIH’s Dale and Betty Bumpers Vaccine Research Center in Bethesda, MD, Dr. Corbett was ready, willing, and able when the COVID-19 pandemic emerged to take the critical first steps in developing what would become the Moderna and Pfizer/BioNTech mRNA vaccines. Recently, she accepted a position at Harvard University T.H. Chan School of Public Health, Boston, where she will soon open her own viral immunology lab to help inform future vaccine development for coronaviruses and other respiratory viruses.

While she was preparing for her move to Harvard, I had a chance to speak with Dr. Corbett about her COVID-19 research experience and what it was like to get immunized with the vaccine that she helped to create. Our conversation was part of an NIH Facebook Live event in which we connected virtually from our homes in Maryland. Here is a condensed version of our chat.

Collins: You’ve studied SARS, MERS, and other coronaviruses for many years. Then, in early January 2020, like all of us, you heard that something was going on that sounded worrisome in Wuhan, China. What did you think?

Corbett: Well, the story actually began for me on December 31, 2019. My boss Dr. Barney Graham sent me an email at 6 a.m. that said: “Get ready for 2020.” There had been some news of a respiratory virus outbreak in the Wuhan district of China. I honestly wrote it off as probably a strain of the flu. Then, we got back to NIH after the holidays, and it was determined around January 6 that the virus was for certain a coronavirus. That meant our team would be responding to it.

We sat down and planned to monitor the situation very closely. We knew exactly what to do, based on our past work. We would go into full force to make a vaccine—the one now known as “the Moderna vaccine” —as quickly as possible for testing in a clinical trial. The goal was to make the vaccine in 100 days. And so when the genetic sequence of this new virus came out on January 10, I sprung out of bed and so did everyone on the team. It’s been kind of a whirlwind ever since.

Collins: Tell us a little bit more about that. The sequence got posted on the internet by a Chinese scientist. So you have this sequence, and everyone gathers in NIH’s Vaccine Research Center. Then what happens?

Corbett: The cool thing about this type of technology is you don’t even need the lab to design the vaccine. All you need are the letters, or sequence, that encodes the virus’ genetic material displayed on your computer screen. We could actually do the work from our homes, obviously in close conversation with each other.

This sequence is the virus’s genetic code. Just like humans have families—brothers, sisters, cousins—viruses also have families. So, we could see when looking at the sequence of letters, how similar this particular virus was to viruses that we’ve worked with before in the coronavirus family. It was almost like “A-ha! This is the part of the sequence that represents the protein on the surface of the virus.”

We knew that we could take the sequence of that surface protein and use all of the knowledge that we had from previous years to design a vaccine. And that’s what we did. We took that sequence on our computer screen and said we said this is exactly how we want this vaccine to look. The process was as straightforward as that.

Collins: In other words, you already knew that these coronaviruses have spike proteins on their surface and that’s the thing that’s going to be really useful for making an antibody. You’d already taken this approach in developing a vaccine for MERS, right?

Corbett: Exactly, we’d done that for MERS. Vaccines are basically a way to teach your body how to see a pathogen. Over the years, as vaccinology and technology have progressed, different scientists have figured out that you don’t really need the whole virus as a part of the vaccine. You can just take a small portion of that virus to alert your body.

In this case, taking the spike protein and teaching your immune system how to specifically spot and attack it, you can now protect yourself from COVID-19. So, we used the sequence of that spike protein, with some modifications to make it much better as a vaccine. We then deliver that to you as a message—messenger RNA (mRNA) —to get your muscle cells briefly to make the spike protein. Then, your body sees that spike protein hanging out on your cells and makes a really specific immune response to it. That way the next time your body sees the spike protein, if you ever come into contact with the virus, your immune system is armed and ready to attack.

Collins: Say more about this messenger RNA approach. It’s been so revolutionary and one of the reasons that we got vaccines into people’s arms in just 11 months. Had this approach ever been used before?

Corbett: Yes, messenger RNA technologies have been in development from a basic science perspective for over 15 years. A lot of that work was funded by NIH. Soon after I got to NIH, I attended a meeting in London called Transforming Vaccinology. At the time, Moderna was a smaller company that was working to make messenger RNA technologies, mostly centered around cancer therapies. But they had started to test some flu vaccines that used messenger RNA. My question to the presenter was: “Every single time I see you guys present, it looks like mRNA technology has always worked. Can you tell me a time that it hasn’t?” And he said, “I can’t.”

So, our understanding of how this technology works to make really good vaccines predates this pandemic. I think one of the worries that many people have is how fast and how new this technology is. But all science is compounded knowledge—everything builds on itself.

Collins: Right! We only learned about messenger RNA, because back in the 1950s and 1960s, some researchers decided to figure out how the information in our genetic instruction book, our DNA, can ultimately turn into proteins. It turned out that the message that carries that information is made of RNA.

So, you knew which kinds of letters to program into the messenger RNA vaccine. Would you explain how this vaccine, its messenger RNA, produces a spike protein. Where does that step happen?

Corbett: Your cells are machines built for this kind of thing. I like to remind people that, on a day-in, day-out basis, our cells make proteins—all of the hormones and other things our bodies needs to survive. So, we’re not teaching the cells to do anything different than they would normally do. That’s important to understand.

The way that cells do this is by reading the mRNA sequence. As they’re reading that sequence, they chew it up, like eating it, and say, “Okay, this sequence is for this very specific protein.” Then, they make that protein and push it to the surface of your cells. That’s how it happens.

Collins: And for mRNA vaccines, that’s the point when your immune system says “Wait a minute! I don’t recognize that as part of me, so I’ve got to make an antibody to it.” Then you’re off to the races and develop your immunity. Now that this mRNA vaccine strategy has succeeded for COVID-19, could it be applied to other infectious diseases or even non-infectious conditions?

Corbett: Yes, I heard that about 60 new companies have sprouted up in the last year around messenger RNA technology. They have ideas for different types of infectious disease vaccines and cancer therapies. I expect that this technology will be transformative to medicine in general.

Collins: Here’s a question from social media: “Why does it take two shots for the Pfizer and the Moderna mRNA vaccines? Why isn’t one good enough?”

Corbett: The way that these vaccines work is much like an alarm clock. Imagine your immune system is in bed and the first shot is the alarm clock going off to say, “Hey, wake up and get ready.” And just like I did this morning, the immune system pressed snooze and took a little nap. But when you hear the alarm clock the second time, it’s like someone rushing into your room and pouring a cold bucket of water on you. You have no choice but to get out of bed.

That’s what the second dose of the vaccine does. It pushes your immune response to the next level. That’s why you need two shots to get the type of efficacy that you want and be fully protected for the optimal immune response.

Collins: You were a co-leader of the team that created what became the Moderna vaccine—and you ended up getting immunized with the Moderna vaccine. What did that feel like?

Corbett: It was pretty surreal. I cried. At the end of it, I felt a lot of relief after getting my vaccine, particularly after getting the second dose. There was this breath of fresh air. It was also a birthday present. I got my second dose the day before my 35th birthday, as a birthday present to myself.

Collins: I have to admit, I cried a little bit too after my second dose. It’s just the sense of relief and incredible gratitude that we’ve reached this point. Here we are with vaccines that have 95 percent effectiveness and an incredibly good safety record, which is almost better than we could have hoped for. I’m a person of faith, so there were a lot of my prayers that went into this and it sure felt like they got answered.

Corbett: Yes, same.

Collins: You are out there a lot talking to people about the vaccines. There are still about 100 million Americans that have not yet received their first dose. Many of them still unsure about getting vaccinated. What do you say to those who are on the fence?

Corbett: In this past year, I’ve spent a lot of time talking about the vaccine with people in the community. One thing that I realized, is that I don’t need to say anything unless I’m asked. I think it’s important that I listen first, instead of just speaking.

So I do that, and I try to answer people’s inquiries as specifically as possible. But people have some very broad questions. One thing that is happening is people are seeing vaccines being developed right before their eyes. That can be a little confusing. I try to explain the process, how we went from the preclinical stage all the way to the point of getting the vaccine to hundreds of millions of people. I explain how each step along the way is very highly vetted by regulatory agencies and data safety monitoring committees. I also tell them that the monitoring continues. People from the clinical trials are still being evaluated, and there’s monitoring in the real world as the vaccine is being rolled out. I think that all of those things are really important for people to know.

Collins: Another question from social media: “As a successful scientist, what advice would you give to people who are thinking about a career in science?”

Corbett: If you think you’re interested, you just have to start. There are internship programs, there are scholarship programs, there are shadowing programs all over this country and even globally that can help you get your feet wet. I think the first thing that you want to do with any career is to figure out whether or not you like it. The only way that you can do that is to just explore, explore, explore.

Collins: Didn’t you kind of roll up your sleeves and take the plunge at a young age?

Corbett: Yes, at age 16, I went off and did summer internships at the University of North Carolina. I was able to see first-hand the day-to-day life of science and what being a scientist would look like. That was really important for me. That’s what I mean by exploring.

Collins: And a follow-up question: “Is the biomedical research community welcoming to women of color?”

Corbett: Not always, frankly. I was very fortunate to have been under the wings of a lot of mentors and advocates, who have helped to advance my career to where it is now. I had great mentors at NIH. My graduate school mentor was amazing, and my main collaborator in the coronavirus field was on my dissertation committee. Even prior to this pandemic, when I was doing work that was very obscure, he checked on me very often and made sure that he had a sense of where I wanted to go and how he could help me get there, including collaborating with me.

That kind of thing is very important, particularly for women of color or anyone from a marginalized community. That’s because there will be a point where there might be a glass ceiling. Unfortunately, we don’t necessarily have the tools to break those just yet. So, someone else is going to have to break those down, and most often than not, that person is going to have to be a white man. Finding those people who are allies with you and joining in your fight for your career trajectory is very helpful.

I remember when I was choosing a college, it was a very difficult decision for me. I got accepted into Ivy League schools, and I’d gone to all of the scholarship weekends all over the country. When I was making the decision, my dad said, “Kizzy, just always go where there is love.”

That really sticks to me with every single choice that I make around my career. You want to be at a place that’s welcoming, a place that understands you, and a place that fosters the next version of who you are destined to be. You need to make sure to step back outside of the day-to-day stuff and say, “Okay, does this place love me and people like me?” It’s important to remember that’s how you thrive: when you are comfortable in and in love with your environment.

Collins: Yes, we have to move our scientific workforce into a place where it is not necessary for a white man to advocate for a talented Black woman. There’s something very wrong with that particular circumstance. As NIH Director, I want to assure you, we are motivated more than ever to change that, including through a new initiative called UNITE. We’re missing out on welcoming the talents of so many folks who currently don’t see our research agenda as theirs, and we need to change that.

Kizzmekia, this has been a lot of fun. Thank you for giving us a half-hour of your time when you’re in the midst of this crazy two-week period of moving from Bethesda to Boston. We wish you the very best for this next chapter, which I know is going to be just amazing.

Corbett: Thank you so much.

Links:

Video: COVID-19 mRNA Vaccine Q & A – Kizzmekia Corbett and Francis Collins (NIH)Video: Lead COVID-19 scientist Kizzmekia Corbett to join Harvard Chan School faculty (Harvard University, Boston)COVID-19 Research (NIH)Dale and Betty Bumpers Vaccine Research Center (National Institute of Allergy and Infectious Diseases/NIH)UNITE Initiative (NIH)

Read more →

Study identifies trigger for 'head-to-tail' axis development in human embryo

Scientists have identified key molecular events in the developing human embryo between days 7 and 14 — one of the most mysterious, yet critical, stages of our development.
The second week of gestation represents a critical stage of embryo development, or embryogenesis. Failure of development during this time is one of the major causes of early pregnancy loss. Understanding more about it will help scientists to understand how it can go wrong, and take steps towards being able to fix problems.
The pre-implantation period, before the developing embryo implants into the mother’s womb, has been studied extensively in human embryos in the lab. On the seventh day the embryo must implant into the womb to survive and develop. Very little is known about the development of the human embryo once it implants, because it becomes inaccessible for study.
Pioneering work by Professor Magdalena Zernicka-Goetz and her team developed a technique, reported in 2016, to culture human embryos outside the body of the mother beyond implantation. This enabled human embryos to be studied up to day 14 of development for the first time.
In a new study, the team collaborated with colleagues at the Wellcome Sanger Institute to reveal what happens at the molecular level during this early stage of embryogenesis. Their findings provide the first evidence that a group of cells outside the embryo, known as the hypoblast, send a message to the embryo that initiates the development of the head-to-tail body axis.
When the body axis begins to form, the symmetrical structure of the embryo starts to change. One end becomes committed to developing into the head end, and the other the ‘tail’.
The new results, published today in the journal Nature Communications, reveal that the molecular signals involved in the formation of the body axis show similarities to those in animals, despite significant differences in the positioning and organisation of the cells.
“We have revealed the patterns of gene expression in the developing embryo just after it implants in the womb, which reflect the multiple conversations going on between different cell types as the embryo develops through these early stages,” said Professor Magdalena Zernicka-Goetz in the University of Cambridge’s Department of Physiology, Development and Neuroscience, and senior author of the report.
She added: “We were looking for the gene conversation that will allow the head to start developing in the embryo, and found that it was initiated by cells in the hypoblast — a disc of cells outside the embryo. They send the message to adjoining embryo cells, which respond by saying ‘OK, now we’ll set ourselves aside to develop into the head end.'”
The study identified the gene conversations in the developing embryo by sequencing the code in the thousands of messenger RNA molecules made by individual cells. They captured the evolving molecular profile of the developing embryo after implantation in the womb, revealing the progressive loss of pluripotency (the ability of the embryonic cells to give rise to any cell type of the future organism) as the fates of different cells are determined.
“Our goal has always been to enable insights to very early human embryo development in a dish, to understand how our lives start. By combining our new technology with advanced sequencing methods we have delved deeper into the key changes that take place at this incredible stage of human development, when so many pregnancies unfortunately fail,” said Zernicka-Goetz.
Story Source:
Materials provided by University of Cambridge. The original story is licensed under a Creative Commons License. Note: Content may be edited for style and length.

Read more →

Focus on emotions is key to improving heart health in people living with obesity

People living with obesity who attended a non-judgemental and personalised lifestyle modification programme improved their cardiovascular and mental health during just 10 weeks, according to a study presented today at EuroHeartCare — ACNAP Congress 2021, an online scientific congress of the European Society of Cardiology (ESC).1 Participants lost weight and achieved benefits in anxiety and depression and physical measurements including blood pressure.
“We focus on changing behaviours and improving people’s relationship with food,” said study author Ms. Aisling Harris, cardiac and weight management dietitian, Croi Heart and Stroke Centre, Galway, Ireland. “Many participants have tried diets with strict rules and have fears about foods they can’t eat. Our programme has no diet or meal plan, and no foods are excluded. Each person sets their own goals, which are reviewed weekly, and our approach is non-judgemental, which builds rapport and gains trust.”
“Obesity develops for multiple reasons and blaming someone for their weight can stop them from getting healthcare and advice,” said Ms. Harris. “It can lead to emotional eating and feeling too self-conscious to exercise. By identifying each person’s triggers, we can develop alternative coping strategies, all within the context of their job, caring responsibilities, external stresses, and so on. For some people, coming to a group like this might be the only social contact that they’ve had in the week or that they’ve had in years. People share experiences and support their peers.”
Both overweight and obesity are associated with an increased risk of dying from cardiovascular disease.2 Weight loss is recommended to reduce blood pressure, blood lipids, and the risk of developing type 2 diabetes, and thus lower the likelihood of heart disease. This study analysed the impact of a community-based, lifestyle modification programme on the physical and mental health of people living with obesity referred from a specialist bariatric service at Galway University Hospital. The researchers reviewed data from 1,122 participants between 2013 and 2019.
The 10-week Croí CLANN (Changing Lifestyle with Activity and Nutrition) programme started with an assessment by a nurse, dietitian and physiotherapist and baseline measurements of weight, blood pressure, cholesterol, blood glucose, fitness, and levels of anxiety and depression. Personalised goals and a management plan were agreed in collaboration with each patient.
Participants attended a 2.5-hour session each week for 8 weeks. The first 30 minutes were devoted to one-to-one goal setting. Next was a 1-hour exercise class led by the physiotherapist. A 1-hour health promotion talk followed on topics such as healthy eating, portion sizes, reading food labels, emotional versus physical hunger, stress management techniques (e.g. meditation), physical activity, sedentary behaviour, cardiovascular risk factors, and making and maintaining changes. Participants used activity trackers and kept food diaries to identify triggers for emotional eating.
In the last week patients had an end of programme assessment with the nurse, dietitian and physiotherapist to look at outcomes. They were then referred back to the hospital.
At baseline, the average body mass index (BMI) was 47.0 kg/m2 and 56.4% of participants had a BMI above 45 kg/m2. In addition, 26.7% had type 2 diabetes, and 31.4% had a history of depression.
More than three-quarters of participants (78%) completed the programme. Psychosocial health was assessed using the 21-point Hospital Anxiety and Depression Scale (HADS), where 0-7 is normal, 8-10 is mild, 11-15 is moderate, and 16-21 is severe. Anxiety and depression scores decreased by 1.5 and 2.2 points, respectively, over the course of the programme. The proportion with an anxiety score greater than 11 at the start was 30.8% and reduced to 19.9%; for depression the corresponding proportions were 21.8%, falling to 9.5%.
The average reduction in body weight was 2.0 kg overall, with 27.2% of participants losing more than 3% of their initial weight. The proportion achieving recommended physical activity levels rose by 31%. There were significant reductions in total cholesterol, low-density lipoprotein (LDL) cholesterol, and blood pressure. The proportion with high blood pressure fell from 37.4% at baseline to 31.1% at 10 weeks. In those with type 2 diabetes, the proportion achieving the recommended blood sugar target rose from 47.6% to 57.4%.
Ms. Harris concluded: “Nearly eight in ten people finished the programme which suggests that the content and format were acceptable. We observed improvements across all psychosocial and health outcomes during a relatively short period indicating that this could be a model of service delivery for other centres.”

Read more →

Stress during pandemic linked to poor sleep

Many people likely lost sleep over COVID-19. A study of twins led by Washington State University researchers found that stress, anxiety and depression during the first few weeks of the pandemic were associated with less and lower quality sleep.
In a survey of more than 900 twins taken shortly after COVID-19 lockdown measures began, about half of the respondents reported no change in their sleep patterns, but around a third, 32.9%, reported decreased sleep. Another 29.8% reported sleeping more. In the analysis, the researchers found that any change in sleep was connected to self-reported mental health issues, though it was more strongly associated with decreased sleep.
“The results show that deviations from your typical sleep behavior may be associated with depression, anxiety and stress,” said Siny Tsang, lead author on the study published in Frontiers in Neuroscience.
Tsang, a staff scientist with the WSU Elson S. Floyd College of Medicine, emphasized that this showed a connection, not a cause, but the study supports previous research that has found a two-way relationship between disrupted sleep patterns and poor mental health. In other words, when people don’t sleep well, they are more likely to feel stress, anxiety and depression, and when they are dealing with those same problems, they are more likely to sleep less — and sometimes more — than the typical six to nine hours a night.
This study analyzes survey responses collected between March 26 and April 5, 2020 from participants in the Washington State Twin Registry. Since then, the same group has answered three more waves of survey questions. Researchers are particularly interested in studying twins, so they can investigate whether associations are mediated by genetic factors, shared environment, or both. The pandemic also offered an opportunity for a natural experiment to see how a stressful situation affects sleep amount and quality among individuals in the community, Tsang said.
The research relies on the self-reported perception of sleep length and quality, but the researcher said that when it comes to mental health, perception can matter more than the real amount of sleep.
“Even if your cell phone says you consistently sleep eight hours every day, you may feel that you slept less or slept poorly, and that may be linked to stressful or anxious feelings,” Tsang said. “It may not matter whether or not the actual number has changed. It’s how you are feeling that is associated with your mental health.”
WSU researchers have also conducted twin-studies on COVID-19 lockdown effects on alcohol use and pandemic stress and exercise. These have all been initial studies taken at the early stages of the pandemic and associated social distancing measures. The scientists are still analyzing results of later surveys, but they are starting to see a common theme.
“A pattern that is consistent across these three studies is that people who reported change in physical exercise, alcohol use or sleep are more stressed, anxious and depressed than those who had said that they have had no change,” Tsang said.
Story Source:
Materials provided by Washington State University. Original written by Sara Zaske. Note: Content may be edited for style and length.

Read more →

Nations weigh mandates and incentives to drive up vaccination rates.

The coronavirus pandemic has exposed economic and social fault lines around the globe, but Covid-19 vaccines have made the divides even starker: While some poor countries are pleading for doses to save their people, a few rich ones are awash in shots and lacking takers.A handful of U.S. states, for example, have tried incentives to get more people vaccinated. But in Moscow, as Covid hospitalizations surged this week, the city government took a harder line, mandating vaccinations for many workers in public-facing jobs.Some other governments have also attempted to require vaccines. A province in Pakistan has said it will stop paying the salaries of civil servants who are not inoculated, starting next month. And Britain, which is seeing a surge attributed to the spread of the Delta variant of the virus, is weighing whether to make shots obligatory for all health care workers.The Moscow Times quoted the city’s mayor, Sergei S. Sobyanin, as saying on Wednesday, “When you go out and come into contact with other people, you are an accomplice of the epidemiological process — a chain in the link spreading this dangerous virus.” The mandate he announced focuses on the education, entertainment, health care, and hospitality sectors and will continue until at least 60 percent of employees have been vaccinated, the newspaper reported.In Britain, officials said that requiring health care workers to be vaccinated would help stop the spread of the virus in hospitals. Nadhim Zahawi, the British vaccine minister, said that there was a precedent for such a requirement. “Obviously, surgeons get vaccinated for hepatitis B, so it’s something that we are absolutely thinking about,” he told Sky News last month.Many universities in the United States now require at least some students and employees to be vaccinated, and federal officials have repeatedly made clear that most companies with at least 15 employees have the right to require that workers are inoculated.But vaccine requirements continue to face resistance from some.In 15 American states, not a single college had announced any type of vaccine requirement as of last month. Days ago, 178 employees of Houston Methodist Hospital who refused to get a coronavirus shot were suspended. And on Saturday, protesters are expected at the offices of the New York State Bar Association in Albany, where officials will be discussing a report that recommends mandating a coronavirus vaccine for all New Yorkers, unless they are exempted by doctors.But for the undecided who are open to persuasion, incentives to get the vaccine remain common: There are lotteries in California, college scholarships in New York State and free drinks in New Jersey.The giveaways have spurred some to action. This week, both New York and California announced that they were lifting virtually all coronavirus restrictions on businesses and social gatherings.

Read more →

Children with asymptomatic malaria a 'hidden risk' to disease control efforts

The role of people infected with malaria without showing symptoms presents a hidden risk to efforts to control the disease after they were found to be responsible for most infections in mosquitoes, according to a study published in The Lancet Infectious Diseases.
Researchers from the Infectious Diseases Research Collaboration (IDRC), London School of Hygiene & Tropical Medicine (LSHTM), Radboud university medical center and University of California, San Francisco, found asymptomatic children in the Uganda study were the biggest source of malaria parasites transmitted to mosquitoes. This could provide a new opportunity for control efforts by targeting this infectious reservoir.
Malaria presents a major health threat globally, with 94% of cases on the African continent alone, according to the WHO World Malaria Report 2020. The disease is passed to a human through the bite of an infected female Anopheles mosquito causing infection with the parasite. The predominant and most deadly parasite, Plasmodium falciparum, accounts for over 75% of mortality worldwide and is highly prevalent in Uganda.
Malarial parasites depend on a life cycle in which they constantly move back and forth between humans and mosquitoes. Successfully interrupting transmission of the disease can involve clearing parasites from human ‘hosts’ using anti-malaria drugs.
Nagongera sub-county (Tororo district) in eastern Uganda has historically very high malaria transmission but following intensive malaria control efforts, such as insecticide-treated bednets, indoor residual spraying (IRS) with insecticides and access to malaria drugs, infections — or at least symptomatic cases — have gone down remarkably.
The research team aimed to investigate patterns of malaria infection and understand more about transmission in the area. The study involved two years of regularly testing more than 500 people for evidence of malaria parasites. The genetic make-up of parasites was determined, as well as their ability to infect mosquitoes.

Read more →

Scientists unravel the function of a sight-saving growth factor

Researchers at the National Eye Institute (NEI) have determined how certain short protein fragments, called peptides, can protect neuronal cells found in the light-sensing retina layer at the back of the eye. The peptides might someday be used to treat degenerative retinal diseases, such as age-related macular degeneration (AMD). The study published today in the Journal of Neurochemistry. NEI is part of the National Institutes of Health.
A team led by Patricia Becerra, Ph.D., chief of the NEI Section on Protein Structure and Function, had previously derived these peptides from a protein called pigment epithelium-derived factor (PEDF), which is produced by retinal pigment epithelial cells that line the back of the eye.
“In the eye, PEDF protects neurons from dying. It prevents the invasion of blood vessels, it prevents inflammation, it has antioxidant properties — all these are beneficial properties,” said Becerra, the senior author of the study. Her studies suggest that PEDF is part of the eye’s natural mechanism for maintaining eye health. “PEDF may have a role for treating eye disease. If we want to exploit the protein for therapeutics, we need to separate out the regions responsible for its various properties and determine how each of them works.”
The team used a well-known cell culture model system where immature retinal cells are isolated from the eyes of newborn rats and grown in a dish with minimal nutrients. The system includes not only the retina’s light-sensing photoreceptors, but additional types of neurons that help the retina process and transmit visual information to the brain.
“Our model system — using cells isolated from the animal — lets us tease out the individual processes and mechanisms behind PEDF’s protective effects,” said Germán Michelis, graduate student and the study’s first author.
The PEDF protein has functionally distinct domains. The Becerra lab previously found that each domain can work independently. One area, which is called the 34-mer because it is formed by 34 amino acid building blocks, halts blood vessel growth. Aberrant blood vessel growth is central to retinal diseases such as AMD and diabetic retinopathy. The second PEDF domain, called the 44-mer, provides anti-death signals to retinal neurons. The 44-mer can also stimulate neurons to grow neurites, finger-like projections that help the neurons communicate with their neighbors. A shorter version of the 44-mer of only 17 amino acids (17-mer) has identical activities.

Read more →